The University of Texas System

Argenx Bv

Argenx Bvba

Johannes De Haard

Torsten Dreier

Peter Ulrichts

Christophe Blanchetot

E Sally Ward Ober

Nicolas G H Ongenae

Antonio Guglietta

Nicolas Leupin

Nicolas Gh Ongenae

Nicolas GH Ongenae

Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.

Use of FCRN antagonists for treatment of generalized myasthenia gravis

Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.

FcRn antagonists and methods of use

FCRN antagonists and methods of use

Growing community of inventors

NA Oudelande, Netherlands

Johannes De Haard